Genmab A/S

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 09:50:00 13/02/2026 pm IST			5-day change	1st Jan Change
1,904.50 ^DKK	+1.25%		-2.73%	-6.04%

13/02	Diary - Europe's STOXX 600 Corporate Earnings Week Ahead	RE
21/01	DNB Carnegie Upgrades Genmab to Buy, Raises PT	MT

Genmab A/S Reaffirms Earnings Guidance for the Year 2025

Published on 12/29/2025 at 06:41 pm IST

S&P Capital IQ

GENMAB A/S

+1.25%

Genmab A/S reaffirmed earnings guidance for the year 2025. For the period, the company announced on December 29, 2025, that its decision to discontinue further clinical development of acasunlimab does not impact the company's full-year 2025 financial guidance.

Latest news about Genmab A/S

13/02	Diary - Europe's STOXX 600 Corporate Earnings Week Ahead	RE
21/01	DNB Carnegie Upgrades Genmab to Buy, Raises PT	MT
21/01	Genmab Posts Higher Darzalex Net Sales in FY25	MT
21/01	Genmab Announces Net Sales of DARZALEX (daratumumab) for 2025	CI
21/01	Genmab says net sales of Darzalex in 2025 $14,351 mln	RE
21/01	Genmab: Darzalex Sales Reach Nearly $14.4 Billion in 2025	FW
21/01	DNB Carnegie Upgrades Genmab to Buy (Hold), Raises Target Price to 2,235 Danish Kroner (from 1,985)	FW
20/01	BofA Lifts Genmab Price Target, Estimates on Expected 'Catalyst Rich' FY26	MT
19/01	SHB: Overreaction in the Market to Genmab's Epkinly Study	FW
19/01	Genmab's Phase 3 Study with Epcoritamab Fails to Meet Overall Survival Endpoint	FW
17/01	AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma	CI
17/01	AbbVie, Genmab Lymphoma Treatment Shows Improved Progression-Free Survival	DJ
17/01	Genmab Says Epcoritamab Improves Progression-Free Survival in Phase 3 Lymphoma Study	MT
17/01	Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study	RE
17/01	Genmab's blood cancer drug fails main goal in late-stage study	RE

Chart Genmab A/S

Duration

Period

GMAB: Dynamic Chart

Company Profile

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (80.6%); - income from research and development (9.3%); - other (10.1%): primarily income from partnership agreement. At the end of 2024, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Net sales are distributed geographically as follows: Denmark (91.9%), the United States (4.2%) and Japan (3.9%).

Employees

2,681

Sector

Biotechnology & Medical Research

Calendar

19/03 - Annual General Meeting

More about the company